 Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
| Descriptor ID |
D018931
|
| MeSH Number(s) |
D27.505.954.248.169
|
| Concept/Terms |
Antineoplastic Agents, Hormonal- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 1 | 2 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 4 | 6 | | 2005 | 4 | 1 | 5 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 3 | 5 | | 2009 | 2 | 0 | 2 | | 2010 | 3 | 3 | 6 | | 2012 | 1 | 4 | 5 | | 2013 | 4 | 3 | 7 | | 2014 | 3 | 2 | 5 | | 2015 | 4 | 2 | 6 | | 2016 | 2 | 3 | 5 | | 2017 | 4 | 1 | 5 | | 2018 | 4 | 2 | 6 | | 2019 | 3 | 2 | 5 | | 2020 | 2 | 5 | 7 | | 2021 | 3 | 2 | 5 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 4 | 5 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.
-
Ding K, Chen L, Levine KM, Sikora MJ, Tasdemir N, Dabbs D, Jankowitz R, Hazan R, Shah O, Atkinson J, Lee AV, Oesterreich S. FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role. Breast Cancer Res Treat. 2025 Jun; 211(2):501-515.
-
Ward AV, Riley D, Cosper KE, Finlay-Schultz J, Brechbuhl HM, Libby AE, Hill KB, Varshney RR, Kabos P, Rudolph MC, Sartorius CA. Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells. Breast Cancer Res. 2025 Mar 07; 27(1):32.
-
Schiavon A, Saba L, Evaristo C, Petiti J, Pignochino Y, Ferrero G, Giordano G, Tucciarello C, Puglisi S, Reimondo G, Terzolo M, Lo Iacono M. Mitotane activates ATF4/ATF3 axis triggering endoplasmic reticulum stress in adrenocortical carcinoma cells. Biomed Pharmacother. 2025 Mar; 184:117917.
-
Del Rivero J, Else T, Hallanger-Johnson J, Kiseljak-Vassiliades K, Raj N, Reidy-Lagunes D, Srinivas S, Gilbert J, Vaidya A, Aboujaoude E, Bancos I, Tito Fojo A. A review of mitotane in the management of adrenocortical cancer. Oncologist. 2024 Sep 06; 29(9):747-760.
-
Azim HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ru?z-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FA. Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy. J Clin Oncol. 2024 Aug 10; 42(23):2822-2832.
-
Wierman ME. Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer? Lancet Oncol. 2024 May; 25(5):534-535.
-
Mart?n M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, P?rez-Moreno PD, Sohn J. Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. J Clin Oncol. 2024 Jun 20; 42(18):2149-2160.
-
Wierman ME, Vassiliades KK. ADRENOCORTICAL CARCINOMA: AN ORPHAN MALIGNANCY: FROM THE PATIENT TO THE BENCH AND BACK. Trans Am Clin Climatol Assoc. 2024; 134:113-122.
-
Schiavon A, Saba L, Catucci G, Petiti J, Puglisi S, Borin C, Reimondo G, Gilardi G, Giachino C, Terzolo M, Lo Iacono M. Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients' Management. Int J Mol Sci. 2023 Nov 24; 24(23).
-
Semina SE, Alejo LH, Chopra S, Kansara NS, Kastrati I, Sartorius CA, Frasor J. Identification of a novel ER-NF?B-driven stem-like cell population associated with relapse of ER+?breast tumors. Breast Cancer Res. 2022 12 08; 24(1):88.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|